Sigyn Therapeutics to offer Class A units, to apply to list on Nasdaq

Sigyn Therapeutics has filed with the SEC for a firm commitment public offering of Class A units, with each Class A unit consisting of one share of its common stock and one Series A warrant to purchase one share its common stock. The common stock currently trades on the OTCQB Venture Market under the symbol "SIGY" and the company said it plans to apply to have its shares of common stock listed on the Nasdaq Capital Market under the symbol "SIGY." The prospectus filed with the SEC states in part: "Sigyn Therapeutics is a development-stage company focused on addressing unmet needs in global health and biodefense. Sigyn Therapy is a broad-spectrum blood purification technology designed to extract viral pathogens, bacterial toxins, and inflammatory mediators from the bloodstream. We are a development stage company with no approved medical products. Candidate indications for Sigyn Therapy include pathogen-associated conditions that precipitate Sepsis, Community Acquired Pneumonia, Emerging Bioterror and Pandemic threats, and End-Stage Renal Disease patients with endotoxemia and elevated inflammatory cytokine production. Beyond our focus to clinically advance Sigyn Therapy, we intend to develop a pipeline of extracorporeal blood purification therapies. In this regard, we have filed patent and trademark submissions related to a preclinical-stage system to enhance the delivery of cancer chemotherapy and reduce its toxicity."